Evidence map›Paper›PMID 38778081›Full record

ArticleEuropean journal of human genetics : EJHG2024

Germline NPAT inactivating variants as cause of hereditary colorectal cancer.

Mariona Terradas, Stephanie A Schubert, Julen Viana-Errasti, Dina Ruano, Gemma Aiza, Maartje Nielsen, Paula Marciel, Carli M Tops, Genís Parra, Hans Morreau and 6 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Hitting the heights with CiteScore.European journal of human genetics : EJHG · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mariona Terradas *Hereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-7813-1172
Stephanie A Schubert *Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0002-8655-1350
Julen Viana-ErrastiHereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-9672-6951
Dina RuanoDepartment of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.
Gemma AizaHereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Maartje NielsenDepartment of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0002-5351-1870
Paula MarcielHereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Carli M TopsDepartment of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
Genís ParraCNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Hans MorreauDepartment of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0001-5083-532X
David TorrentsLife Sciences Department, Barcelona Supercomputing Centre (BSC), Barcelona, Spain.
Monique E van LeerdamDepartment of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0002-5719-3208
Gabriel CapelláHereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-4669-7320
Noel F C C de MirandaDepartment of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.
Laura ValleHereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.ORCID 0000-0003-0371-0844
Tom van WezelDepartment of Pathology, Leiden University Medical Centre, Leiden, The Netherlands. t.van_wezel@lumc.nl.ORCID 0000-0001-5773-7730

Funding

Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) AECC InvestigadorGeneralitat de Catalunya (Government of Catalonia) AGAUR 2017SGR1282; CERCA ProgramMaag Lever Darm Stichting (Dutch Digestive Foundation) MLDS FP13-13Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2020-112595RB-I00Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CIBERONC CB16/12/00234
6 · The paper itself

Abstract

Two independent exome sequencing initiatives aimed to identify new genes involved in the predisposition to nonpolyposis colorectal cancer led to the identification of heterozygous loss-of-function variants in NPAT, a gene that encodes a cyclin E/CDK2 effector required for S phase entry and a coactivator of histone transcription, in two families with multiple members affected with colorectal cancer. Enrichment of loss-of-function and predicted deleterious NPAT variants was identified in familial/early-onset colorectal cancer patients compared to non-cancer gnomAD individuals, further supporting the association with the disease. Previous studies in Drosophila models showed that NPAT abrogation results in chromosomal instability, increase of double strand breaks, and induction of tumour formation. In line with these results, colorectal cancers with NPAT somatic variants and no DNA repair defects have significantly higher aneuploidy levels than NPAT-wildtype colorectal cancers. In conclusion, our findings suggest that constitutional inactivating NPAT variants predispose to mismatch repair-proficient nonpolyposis colorectal cancer.

Indexed as

Germ-Line MutationAdultAgedCell Cycle ProteinsColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisFemaleHumansLoss of Function MutationMaleMiddle AgedPedigreeCell Cycle ProteinsNPAT protein, human

Identifiers

PMID38778081
PMCPMC11219789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.